Novartis's Rydapt wins EU approval for AML, other diseases | | ZURICH (Reuters) - Swiss drugmaker Novartis on Wednesday said it had won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases, adding to U.S. approvals it secured in April. |
| |
As clock ticks, Republicans try to move ahead on Obamacare repeal | | WASHINGTON (Reuters) - The Trump administration and top U.S. Senate Republicans pushed on Tuesday for action on a bill to dismantle Obamacare, but time was running out and they were still hunting for the votes needed to pass their latest attempt to gut the 2010 healthcare law. |
| |
| | |